posted on 2020-12-08, 15:06authored byPaola Munoz-Tello, Hua Lin, Pasha Khan, Ian Mitchelle S. de Vera, Theodore M. Kamenecka, Douglas J. Kojetin
Nurr1/NR4A2 is an orphan nuclear
receptor transcription factor
implicated as a drug target for neurological disorders including Alzheimer’s
and Parkinson’s diseases. Previous studies identified small-molecule
NR4A nuclear receptor modulators, but it remains unclear if these
ligands affect transcription via direct binding to Nurr1. We assessed
12 ligands reported to affect NR4A activity for Nurr1-dependent and
Nurr1-independent transcriptional effects and the ability to bind
the Nurr1 ligand-binding domain (LBD). Protein NMR structural footprinting
data show that amodiaquine, chloroquine, and cytosporone B bind the
Nurr1 LBD; ligands that do not bind include C-DIM12, celastrol, camptothecin,
IP7e, isoalantolactone, ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate
(TMPA), and three high-throughput screening hit derivatives. Importantly,
ligands that modulate Nurr1 transcription also show Nurr1-independent
effects on transcription in a cell type-specific manner, indicating
that care should be taken when interpreting the functional response
of these ligands in transcriptional assays. These findings should
help focus medicinal chemistry efforts that desire to optimize Nurr1-binding
ligands.